{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["19(2)"],"submitter":["Leal L"],"pubmed_abstract":["In 2020, COVID-19 caused a global health crisis, prompting research efforts and accelerating drug development. As part of this response, we conducted a phase 2b, multicentre, open-label, randomized (1:1) clinical trial to compare the effects of siltuximab versus corticosteroids on disease progression in hospitalized adults with COVID-19 pneumonia. Between April 2020 and January 2021, 82 patients were randomized to receive siltuximab and 80 corticosteroids (20 methylprednisolone and 60 dexamethasone). Median (IQR) age was 61 years (50-72). Nineteen patients allocated to siltuximab were admitted to the intensive care unit compared to eight receiving corticosteroids (p = 0.025). Corticosteroid treatment was independently associated with a higher risk of avoiding intensive care unit admission "],"journal":["Clinical and translational science"],"pagination":["e70491"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12874496"],"repository":["biostudies-literature"],"pubmed_title":["Effects of Siltuximab Versus Corticosteroids in Preventing COVID-19 Pneumonia Disease Progression: Multicentre, Open-Label, Randomized Clinical Trial."],"pmcid":["PMC12874496"],"pubmed_authors":["Carbonell I","Vergara A","Paredes R","Castro P","Laguno M","Segui F","Marco-Hernandez J","Pich J","Chumbita M","Puerta-Alcalde P","Padrosa J","Castan C","Ferrer E","Gonzalez-Cordon A","Rico V","SILCOR study group","Fernandez S","Soriano A","Calvo J","Muelas M","Marcos MA","Rojas J","Camprubi D","Lopez-Soto A","Sola M","Dalmau D","Almuedo A","Garcia F","Ventosa H","Feliu M","Tuset M","de Alba MT","Bodro M","Capdevila A","Gabara C","Carbonell C","Garcia-Vidal C","Ribot J","Naval J","Tellez A","Rodriguez N","Matas A","Aldea A","Pinazo MJ","Ladino A","de Lazzari E","Del Puerto Bernoy Gonzalez M","Martinez JA","Aguero D","Moreno A","Meira F","Del Rio A","Garcia-Pouton N","Munoz J","Ambrosioni J","Rubio E","Hernandez-Meneses M","Pellice M","Marti H","Leal L","Ugarte A","Torres B","Fernandez M","Herrera S","Alvarez M","Foncillas A","Morata L","Rodriguez-Nunez O","Cardozo C","Duenas G","Inciarte A","Zamora-Martinez C","Tome A","Prieto-Gonzalez S","de la Mora L","Grau B","Grafia I","Moreno P"],"additional_accession":[]},"is_claimable":false,"name":"Effects of Siltuximab Versus Corticosteroids in Preventing COVID-19 Pneumonia Disease Progression: Multicentre, Open-Label, Randomized Clinical Trial.","description":"In 2020, COVID-19 caused a global health crisis, prompting research efforts and accelerating drug development. As part of this response, we conducted a phase 2b, multicentre, open-label, randomized (1:1) clinical trial to compare the effects of siltuximab versus corticosteroids on disease progression in hospitalized adults with COVID-19 pneumonia. Between April 2020 and January 2021, 82 patients were randomized to receive siltuximab and 80 corticosteroids (20 methylprednisolone and 60 dexamethasone). Median (IQR) age was 61 years (50-72). Nineteen patients allocated to siltuximab were admitted to the intensive care unit compared to eight receiving corticosteroids (p = 0.025). Corticosteroid treatment was independently associated with a higher risk of avoiding intensive care unit admission ","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-15T09:07:12.961Z","creation":"2026-07-02T03:08:46.557Z"},"accession":"S-EPMC12874496","cross_references":{"pubmed":["41641848"],"doi":["10.1111/cts.70491"]}}